First Hospitals in the World Adopt Genesis Robotic Technology for Cardiac Heart Rhythm Disorders
September 14 2020 - 9:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced it has completed installations of the world’s first
Genesis Robotic Magnetic Navigation (RMN) systems to treat heart
rhythm disorders at Helsinki University Hospital in Finland and
Banner - University Medicine Heart Institute in Phoenix, Arizona.
“The clinical benefits of robotics in
electrophysiology have been extensively documented at our hospital
over many years,” said Dr. Pekka Raatikainen, Chief of
Electrophysiology and Pacing at the Heart and Lung Center at
Helsinki University Central Hospital. “With the adoption of the
first Genesis systems in the world, we are proud to be a pioneer in
the process of advancing robotic technology for the benefits of
patients and the medical community.”
“The capabilities of robotics are growing at a
rapid rate, moving us toward a paradigm shift in our practice,”
said Dr. J. Peter Weiss, Director of Ventricular Arrhythmia
Management and Robotics at Banner - University Medicine Heart
Institute. “I am extremely excited to play a part in bringing this
advanced technology to our community of patients and heart rhythm
specialists throughout Phoenix and beyond.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias, abnormal
heart rhythms that result when the heart beats too quickly, too
slowly, or with an irregular pattern. When left untreated, certain
arrhythmias can significantly increase the risk of stroke, heart
failure, and sudden cardiac arrest. The Genesis RMN® system
provides the established benefits and reliability of RMN in a
highly innovative architecture that is faster, smaller, lighter,
and more flexible. Adopting the Genesis RMN system reflects a
commitment to using the most advanced technologies to enhance
patient care.
“Patients with medical conditions from the most
complex to the most common seek us out for care in part because we
remain on the cutting edge in technology and safety,” said Kristi
McShay, Assistant Vice President for the Cardiovascular Line at
Banner Health. “We are pleased to be the first in the nation to
offer this new generation of robotics for treating heart rhythm
disorders.”
“This technology allows us to positively address
the increasing number of patients with complex arrhythmias. In
addition, it provides us a competitive advantage to other Nordic
centers concerning education and learning,” said Antti Vento,
Medical Director of Helsinki Heart and Lung Center.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024